Mayne enters US women’s health market with NASDAQ-listed partner for $205m; shareholders spookedIn a deal the company expects to be immediately material to its own revenues and profits, Australia’s Mayne Pharma (ASX:MYX) is entering the US women’s healthcare product market with NASDAQ-listed partner TherapeuticsMD. Executing a licencing agreement with Therapeutics, Mayne will hand the former $205.5m to fund the product-line acquisition.Payments to Therapeutics MD by Mayne will be made on sales-based milestones; for every US$100m in revenue made each year, Mayne will need to hand TherapeuticsMD $5m. Mayne will also pay royalties of US$3m a year for 12 years.
Mayne Pharma has an extensive women’s health portfolio focused on contraceptives.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.01 |
Change
0.020(0.40%) |
Mkt cap ! $407.8M | |||
| Open | High | Low | Value | Volume |
| $4.98 | $5.03 | $4.98 | $295.1K | 58.95K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 34565 | $5.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.02 | 2526 | 18 |
View Market Depth
| Last trade - 15.02pm 11/08/2025 (20 minute delay) ? |
| MYX (ASX) Chart |